Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that various antiandrogen therapies, including spironolactone and finasteride, effectively address hirsutism, acne, androgenic alopecia, and ovulatory dysfunction in hyperandrogenic women and are generally well tolerated.

This study found that Orthosiphon stamineus extract significantly stimulated dermal papilla cell proliferation and enhanced hair growth in an ex vivo model of androgenic alopecia compared to vehicle-treated controls.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

This study reports experience treating 140 women with hirsutism and other virilism signs using cyproterone acetate and ethinyl estradiol, focusing on those treated for over five months.

The antiandrogen 11α-hydroxyprogesterone effectively reduces skin oil and cholesterol when applied to the skin.

This review discusses the use of spironolactone for common skin diseases like acne and its potential role in daily clinical practice but presents no new clinical results.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study reported that topical spironolactone improved lid margin vascularity, corneal fluorescein staining, and disease severity scores in patients with ocular graft-versus-host disease, suggesting a potential therapeutic role by enhancing corneal lipid production with minimal adverse effects.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.

This review discusses non-oral hormonal contraceptives and other exogenous steroid hormones, reporting they are generally safe for temporary use in women without breast cancer, but data are limited.

This study suggests that finasteride is a safe and effective alternative therapy for women with hidradenitis suppurativa who have contraindications or intolerance to spironolactone.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study found that oral spironolactone 100 mg daily for 24 weeks improved terminal hair counts and diameters in premenopausal women with female pattern hair loss when used alongside minoxidil, despite a higher incidence of menstrual irregularities.

This study found that SER120 nasal spray significantly improved nocturia symptoms and quality of life compared to placebo in patients 50 years and older, with both tested doses showing efficacy and an acceptable safety profile over a 12-week period.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

Skin hormone levels change significantly after menopause.

This review discusses the favorable effects of anti-androgens in treating severe skin conditions like acne, seborrhoea, androgenic alopecia, and hirsutism but reports no new clinical results, emphasizing the importance of understanding side effects and hormone interactions.

This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

This report describes two cases of postmenopausal hyperandrogenism where GnRH analogue use suggested an ovarian source of excess androgens, leading to a diagnosis of benign ovarian tumors.

This study concluded that spironolactone may be an effective therapy for a subgroup of hirsute patients, as it reduced plasma testosterone and improved certain hair growth measures.

This review discusses the potential and varied uses of spironolactone in dermatological conditions such as acne, hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia, emphasizing dosage, treatment recommendations, and adverse effects for practical clinical use.

This case report presents a 60-year-old woman with virilization and elevated adrenal androgens, where a bilateral salpingo-oophorectomy confirmed ovarian steroid cell tumor NOS, and her symptoms resolved post-operatively.

This study found that spironolactone reduced androgenic hormones in hirsute women but had only marginal effects on hair growth, making it no more advisable than other therapies.